+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 16 Actively Recruiting clinical trials

U

Actively Recruiting

Researchers are evaluating whether using an automated Carbon Dioxide CO2 injection system during infrainguinal peripheral vascular interventions PVI can reduce major adverse kidney events within 90 days in patients at moderately increased risk for contrast-associated acute kidney injury CA-AKI. This Phase 3 randomized controlled trial compares a CO2-based contrast medium sparing strategy to the standard use of iodinated contrast media in patients with peripheral vascular and kidney diseases. Participants are randomly assigned to one of two groups. The intervention group receives PVI using an automated CO2 injection system as the primary contrast agent, with iodinated contrast media available as a backup if image quality is insufficient or if the patient cannot tolerate CO2 angiography. The control group undergoes routine PVI using iodinated contrast media according to local standards, avoiding high-osmolar contrast agents. All patients are followed for up to 12 months after their procedure. During the study, participants undergo the planned PVI procedure with either contrast method. Researchers carefully record the amount and reasons for any iodinated contrast media used in the CO2 group. Patients are monitored for kidney-related outcomes, focusing on major adverse kidney events up to 90 days after the intervention. The trial includes ongoing follow-up assessments to evaluate safety and effectiveness over one year.

Age: 18Years +All GendersPhase 3
11 locations
O

Actively Recruiting

The registry is designed to evaluate the outcomes, performance, and safety of BIOTRONIK devices used in conduction system pacing CSP through long-term data collected in real-world clinical settings. It includes patients who receive these devices as part of routine care to better understand their use and effects over time. The study is observational and collects data from unselected patients without intervention by the researchers. Participants receive BIOTRONIK devices for conduction system pacing, including the implantation of the Solia CSP S pacing lead for left bundle branch area pacing LBBAP. The study includes patients who are newly implanted, recently implanted but not yet discharged, or transitioning from a related study. The registry tracks device performance and safety over an average of 4 years through annual assessments. During the study, participants will undergo evaluations including the rate of device-related serious adverse events, success of acute implantation, capture type at implantation, long-term maintenance of pacing, and electrical parameters such as pacing threshold, sensing amplitude, and impedance. Participants will use the BIOTRONIK Home Monitoring system with the CardioMessenger device to support follow-up, which requires their willingness and ability to comply with study visits and monitoring over time.

Age: 18Years +All Genders
46 locations
R

Actively Recruiting

Researchers are evaluating the outcomes of different coronary artery bypass grafting techniques in women with heart disease. The trial compares multiple arterial grafting MAG to single arterial grafting SAG to see if using multiple arterial grafts improves major heart and brain-related events and quality of life. This international randomized clinical trial includes 2,300 women to assess differences in survival, stroke, heart attacks, repeat surgeries, and hospital readmissions, as well as physical and mental health. Participants will be randomly assigned to one of two groups. One group receives a single arterial graft using the left internal thoracic artery plus additional venous grafts. The other group receives multiple arterial grafts, including the left internal thoracic artery and at least one other arterial graft such as the right internal thoracic artery or radial artery, with possible additional arterial grafts. The study uses the infrastructure of an existing trial and follows patients for at least 2.5 years after surgery. During the study, researchers collect data on major adverse cardiac and cerebrovascular events, along with quality of life measured by general and disease-specific questionnaires. Physical and mental health symptoms are also assessed. Follow-up includes tracking deaths, strokes, heart attacks, repeat procedures, and hospital stays. The trial aims to provide detailed information on outcomes and quality of life in women undergoing coronary bypass surgery over a long-term period.

Age: 18Years +FEMALEPhase Not Applicable
146 locations
S

Actively Recruiting

Researchers are evaluating whether performing percutaneous coronary intervention PCI on all significant blockages in patients with non-ST-segment elevation myocardial infarction NSTEMI and multivessel coronary artery disease is better than treating only the main culprit lesion. This open-label, randomized, controlled, multicenter trial aims to compare these two approaches to understand which provides better outcomes for patients with this heart condition. Participants will be randomly assigned to one of two groups. One group will receive optimal medical therapy and PCI only on the culprit lesion, with no further intervention on other blockages unless certain emergency criteria occur. The other group will receive complete revascularization of all significant non-culprit lesions, either during the initial procedure, hospitalization, or within 45 days after the initial PCI. During the study, participants will be followed for an average of two years to monitor outcomes including cardiovascular death, rehospitalization for heart attacks, and other heart-related events. Researchers will also assess quality of life and complications such as bleeding, stroke, and kidney injury at various time points. The study involves regular evaluations and aims to gather comprehensive data to determine the best treatment strategy for these patients.

Age: 18Years +All GendersPhase Not Applicable
58 locations
R

Actively Recruiting

Researchers are evaluating treatments for patients with high-risk pulmonary embolism, a serious condition where blood clots block blood flow in the lungs. The trial compares early catheter-directed treatment plus conventional care against conventional care alone. This open-label, multicenter, randomized controlled trial aims to assess which approach better reduces mortality and severe complications within seven days. Participants are randomly assigned to one of two groups. One group receives conventional care following guidelines, including reperfusion treatments, with catheter-based intervention only if no improvement occurs. The other group undergoes catheter-interventional treatment within 60 minutes of randomization, using certified devices such as aspiration thrombectomy and local fibrinolytic therapy, possibly combined with ultrasound assistance. Sheaths used during the catheter procedures are removed shortly after treatment, and fibrinolytic drugs are prepared concurrently to avoid delays if needed. Throughout the study, researchers monitor participants closely, measuring outcomes like death from any cause, recurrent cardiac arrest, and shock within seven days. Secondary outcomes include mortality at 30 days, bleeding events, use of life support devices, heart function changes via echocardiography, ICU stay length, and time to stabilize blood flow. The trial is led by Leipzig Heart Science gGmbH and participants are followed up to assess these key health indicators.

Age: 18Years +All GendersPhase Not Applicable
18 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
S

Actively Recruiting

Researchers are evaluating the safety and performance of the HighLife 28mm transcatheter, trans-septal Mitral Valve in patients who have moderate to severe mitral regurgitation and are considered high risk for traditional open-heart surgery. This study focuses on patients with significant mitral valve leakage and who have specific heart failure symptoms classified as New York Heart Association NYHA Class II, III, or ambulatory IV. The study is sponsored by HighLife SAS and aims to gather information on this device in a real-world setting without randomization. Participants will receive the HighLife Transcatheter Mitral Valve Replacement device through a trans-septal catheter procedure. This is a single-arm, non-randomized study where all participants undergo this intervention. The study will monitor the devices safety primarily within the first 30 days after implantation. The procedure is designed for patients who meet specific anatomical criteria and have been on guideline-directed medical therapy for at least one month. Throughout the study, participants will be closely followed with scheduled assessments to evaluate the devices safety and overall performance. Researchers will monitor for adverse events and clinical outcomes, focusing on the 30-day safety period after treatment. The study includes follow-up visits and evaluations to ensure participant well-being and to gather comprehensive data on the devices effects. Participation lasts according to the study protocol, with ongoing monitoring as needed.

Age: 18Years +All GendersPhase Not Applicable
50 locations
E

Actively Recruiting

Aortic stenosis AS is a common heart valve problem in older adults, leading to serious symptoms and increased health risks. Transcatheter Aortic Valve Replacement TAVR is a recognized treatment for severe AS, especially for those at high risk with traditional surgery. Many patients with AS also take beta-blockers to manage related heart conditions, but these medications may increase the risk of needing a pacemaker after TAVR due to their effects on heart rhythm. This trial compares two approaches to beta-blocker use in patients undergoing TAVR one group pauses beta-blockers 72 hours before the procedure and resumes them 72 hours after, while the other group continues beta-blockers throughout. The study is open-label and randomized, involving multiple centers, and aims to assess the safety and impact of temporarily stopping beta-blockers around the time of TAVR. Participants will be monitored for outcomes including mortality, rehospitalization due to heart failure, stroke, and severe arrhythmias at 30 days, with additional follow-up for pacemaker implantation and other events up to one year. Researchers will evaluate these measures to understand the effects of beta-blocker management during TAVR, with the overall study lasting until May 2028.

Age: 18Years +All GendersPhase Not Applicable
11 locations
C

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the Myval Transcatheter Heart Valve THV Series compared to Contemporary Valves, including the Sapien THV Series and Evolut THV Series, in patients with severe symptomatic native aortic valve stenosis. This multinational, prospective, randomized trial involves 768 participants and aims to assess whether the Myval device performs at least as well as the other commercially available valves in improving heart valve function. Participants will be randomly assigned to receive either the Myval THV Series or one of the Contemporary Valves via a transfemoral approach. The Myval devices come in various sizes ranging from 20 mm to 29 mm, with additional registries for extra-large sizes. Separate study groups include a non-randomized nested registry for extra-large Myval devices and a lead-in set to ensure procedural adherence by investigators before enrolling subjects. During the study, participants will undergo assessments including clinical evaluations and imaging to monitor valve function and safety over time. Outcomes measured include a combined safety and effectiveness endpoint at 30 days, as well as longer-term monitoring for mortality, stroke, kidney injury, valve performance, and quality of life up to 10 years. The study involves follow-ups at multiple timepoints to comprehensively evaluate the devices performance and patient health.

Age: 18Years +All GendersPhase Not Applicable
54 locations
S

Actively Recruiting

Researchers are studying adults hospitalized with acute heart failure and cardiogenic shock to understand whether information collected during routine hospital care, along with blood and urine samples, can help doctors better identify types of cardiogenic shock and predict patient outcomes. The study focuses on whether clinical findings, imaging results, and biomarkers, including factors specific to sex, relate to the risk of death within 30 days. This observational study does not involve experimental treatments. Participants will have data collected from their routine hospital care and will provide extra blood and urine samples for future research storage. The study follows participants after they leave the hospital to observe outcomes over time. No new treatments are administered during the study. During the study, researchers will monitor participants through routine care records and additional sample collections. They will assess outcomes such as mortality at 30 days, as well as mortality and rehospitalization rates at 6 and 12 months after discharge. The total participation time varies depending on individual hospital discharge and follow-up periods.

Age: 18Years +All Genders
4 locations

1-10 of 16

1